RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
NCT04193696
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
39
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
Sponsor
Guangxi Medical University